133 related articles for article (PubMed ID: 36418167)
21. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
Li HX; Xiang N; Hu WK; Jiao XL
J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
[TBL] [Abstract][Full Text] [Related]
22. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
23. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
24. Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial.
Witte J; Goretzki PE; Dotzenrath C; Simon D; Felis P; Neubauer M; Röher HD
World J Surg; 2000 Nov; 24(11):1303-11. PubMed ID: 11038198
[TBL] [Abstract][Full Text] [Related]
25. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine.
Azizi F; Abdi H; Mehran L; Perros P; Masoumi S; Amouzegar A
Endocr Pract; 2023 Apr; 29(4):240-246. PubMed ID: 36649782
[TBL] [Abstract][Full Text] [Related]
27. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.
Oeverhaus M; Winkler L; Stähr K; Daser A; Bechrakis N; Stöhr M; Chen Y; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1160172. PubMed ID: 37082130
[TBL] [Abstract][Full Text] [Related]
28. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
29. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial.
Leo M; Marcocci C; Pinchera A; Nardi M; Megna L; Rocchi R; Latrofa F; Altea MA; Mazzi B; Sisti E; Profilo MA; Marinò M
J Clin Endocrinol Metab; 2012 Jan; 97(1):E44-8. PubMed ID: 22031515
[TBL] [Abstract][Full Text] [Related]
30. Use of methotrexate to treat isolated Graves ophthalmopathy developing years after thyroidectomy and iodine 131 treatment of papillary thyroid cancer.
Sanyal P; Bing-You RG; Braverman LE
Endocr Pract; 2008; 14(4):422-5. PubMed ID: 18558593
[TBL] [Abstract][Full Text] [Related]
31. [Definitive treatment of Graves' disease in children].
Ivannikova TE; Shiryaeva TY; Nagaeva EV; Sheremeta MS; Brovin DN; Bezlepkina OB
Probl Endokrinol (Mosk); 2022 Apr; 68(2):104-111. PubMed ID: 35488761
[TBL] [Abstract][Full Text] [Related]
32. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
[TBL] [Abstract][Full Text] [Related]
33. [Graves' ophthalmopathy].
Eckstein A; Esser J
Internist (Berl); 2010 May; 51(5):584, 586-8, 590-2, passim. PubMed ID: 20383481
[TBL] [Abstract][Full Text] [Related]
34. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease.
Kim J; Choi MS; Park J; Park H; Jang HW; Choe JH; Kim JH; Kim JS; Cho YS; Choi JY; Kim TH; Chung JH; Kim SW
Thyroid; 2021 Aug; 31(8):1264-1271. PubMed ID: 33947272
[No Abstract] [Full Text] [Related]
35. Graves' ophthalmopathy: the case for thyroid surgery.
Lowery AJ; Kerin MJ
Surgeon; 2009 Oct; 7(5):290-6. PubMed ID: 19848063
[TBL] [Abstract][Full Text] [Related]
36. Clinical update: treatment of hyperthyroidism in Graves' ophthalmopathy.
Azzam I; Tordjman K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():193-7. PubMed ID: 20467362
[TBL] [Abstract][Full Text] [Related]
37. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B
Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495
[No Abstract] [Full Text] [Related]
38. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
39. Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys-Waligórska A; Gołkowski F; Kusnierz-Cabala B; Buziak-Bereza M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(3):214-9. PubMed ID: 21717402
[TBL] [Abstract][Full Text] [Related]
40. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
